The approval of KRAS G12C (G‐glycine, C‐cysteine) inhibitor, sotorasib8, 9 for use in the second‐line setting, has revolutionized the treatment of this subgroup of NSCLC patients. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.